Fungal Infection
Conditions
Keywords
Blood Concentration, Deoxycholic Acid Amphotericin B, Fungal Infection
Brief summary
To explore the PK/PD of deoxycholic amphotericin B in invasive fungal infection patients with sepsis/septic shock;To compare the PK/PD of deoxycholic amphotericin B in invasive fungal infection patients with sepsis and septic shock.
Detailed description
This was a single-center study.Patients who were diagnosed with in invasive fungal infection receieved deoxycholic acid amphotericin B during the study period.The information was recored including the general condition, infection index, PK/PD index and drug-related side effects.
Interventions
DRUGDeoxycholic acid amphotericin B
Starting with 1mg and increasing by 5-25mg daily until the maintenance dose is 50mg/d.
Sponsors
Southeast University, China
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Patients age more than 18 years old; Meet the criteria of Sepsis 3.0; Admitted to ICU; Patients were suspected or diagnosis of IFI,doctors determined the use of deoxycholic acid amphotericin B.
Exclusion criteria
Serum creatinine≥221umol/L; Deoxycholic acid amphotericin B or amphotericin B liposome were used for the past 7 days; Patients being treated with rifampicin; Unable to tolerate treatment of deoxycholic acid amphotericin B; BMI\<18.5 or \>30; Tumors; Pregnancy; Estimated time of survival\<24h; Patients who participated in other studies within 30 days.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cmax/MIC | 14 days | PK/PD of Deoxycholic Acid Amphotericin B |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| AUC24h/MIC | 14 days | Concentration of Deoxycholic Acid Amphotericin B |
Countries
China
Outcome results
None listed